What to Expect From Biogen’s Q3 2025 Earnings Report

Company Overview - Biogen Inc. is valued at a market cap of $22.1 billion and specializes in therapies for neurological, neurodegenerative, and rare diseases [1] - The company has a strong presence in neuroscience, focusing on conditions such as multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer's disease [1] Earnings Forecast - Biogen is scheduled to announce its fiscal Q3 earnings for 2025 on October 30, with analysts projecting a profit of $3.94 per share, a decrease of 3.4% from $4.08 per share in the same quarter last year [2] - For the current year, analysts expect Biogen to report an EPS of $15.83, down 3.9% from $16.47 in fiscal 2024 [3] Stock Performance - Over the past 52 weeks, Biogen's shares have declined by 19.5%, underperforming the S&P 500 Index's increase of 16.3% and the Health Care Select Sector SPDR Fund's drop of 6% [4] - Following the release of Q2 2025 results, Biogen's shares climbed 1.1%, with adjusted EPS of $5.47 and revenues of $2.65 billion exceeding analyst expectations [5] Analyst Ratings - Wall Street analysts have a "Moderate Buy" rating for Biogen, with 14 recommending "Strong Buy," 1 indicating "Moderate Buy," and 19 suggesting "Hold" [6] - The mean price target for Biogen is $173.21, indicating a potential upside of 15.8% from current levels [6]